Enlivex Therapeutics Quote - ENLV

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

1.08

Bid

1.01

Ask

1.09

Volume

0.00 Day's Range 0.00

0.8101 52 Week Range 4.59

Market Cap

22.55M

Previous Close

1.08

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

225,288

Shares Outstanding

20,880,000

Dividend Yield

PE Ratio

-0.78

Earnings Per Share (EPS)

-1.39

Revenue

Net Profit

-29.07M

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threate... Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.enlivex.com

Headquarters

Ness Ziona, Center, Isr

Founded

Enlivex Therapeutics Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ENLV. The last closing price for Enlivex Therapeutics was US$1.08. Over the last year, Enlivex Therapeutics shares have traded in a share price range of US$ 0.8101 to US$ 4.59.

Enlivex Therapeutics currently has 20,880,000 shares outstanding. The market capitalization of Enlivex Therapeutics is US$22.55 million. Enlivex Therapeutics has a price to earnings ratio (PE ratio) of -0.78.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Ness-Ziona, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Nes-Ziona, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Nes-Ziona, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.06	-5.26315789474	1.14	1.15	1	39581	1.10531344	CS
4	-0.1797	-14.2653012622	1.2597	1.2599	1	66203	1.15955178	CS
12	-0.12	-10	1.2	1.3465	0.8101	225288	1.20692783	CS
26	-0.18	-14.2857142857	1.26	1.75	0.8101	159720	1.30586249	CS
52	-1.47	-57.6470588235	2.55	4.59	0.8101	139713	1.67957063	CS
156	-4.04	-78.90625	5.12	8.64	0.8101	76121	2.56571641	CS
260	-6.82	-86.3291139241	7.9	29.4	0.8101	177233	8.86514625	CS

ENLV - Frequently Asked Questions (FAQ)

What is the current Enlivex Therapeutics share price?

The current share price of Enlivex Therapeutics is US$ 1.08

How many Enlivex Therapeutics shares are in issue?

Enlivex Therapeutics has 20,880,000 shares in issue

What is the market cap of Enlivex Therapeutics?

The market capitalisation of Enlivex Therapeutics is USD 22.55M

What is the 1 year trading range for Enlivex Therapeutics share price?

Enlivex Therapeutics has traded in the range of US$ 0.8101 to US$ 4.59 during the past year

What is the PE ratio of Enlivex Therapeutics?

The price to earnings ratio of Enlivex Therapeutics is -0.78

What is the reporting currency for Enlivex Therapeutics?

Enlivex Therapeutics reports financial results in USD

What is the latest annual profit for Enlivex Therapeutics?

The latest annual profit of Enlivex Therapeutics is USD -29.07M

What is the registered address of Enlivex Therapeutics?

The registered address for Enlivex Therapeutics is 14 EINSTEIN STREET, NESS ZIONA, CENTER, 7403618

What is the Enlivex Therapeutics website address?

The website address for Enlivex Therapeutics is www.enlivex.com

Which industry sector does Enlivex Therapeutics operate in?

Enlivex Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Symbol	Price	Vol.
AALAmerican Airlines Group Inc	US$ 16.70 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 73.51 (0.00%)	0
AADIAadi Bioscience Inc	US$ 2.74 (0.00%)	0
AACGATA Creativity Global	US$ 0.78 (0.00%)	0
AALAmerican Airlines Group Inc	US$ 16.70 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 73.51 (0.00%)	0
AADIAadi Bioscience Inc	US$ 2.74 (0.00%)	0
AACGATA Creativity Global	US$ 0.78 (0.00%)	0
AALAmerican Airlines Group Inc	US$ 16.70 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 73.51 (0.00%)	0
AADIAadi Bioscience Inc	US$ 2.74 (0.00%)	0
AACGATA Creativity Global	US$ 0.78 (0.00%)	0

Symbol

Price

Vol.